

Accepted Manuscript



Efficacy and Safety of Ixekizumab Over 4 Years of Open-Label Treatment in a Phase 2 Study in Chronic Plaque Psoriasis

Claus Zachariae, MD, Kenneth Gordon, MD, Alexandra Kimball, MD, Mark Lebwohl, MD, Andrew Blauvelt, MD, Craig Leonardi, MD, Daniel Braun, MD, Missy McKean-Matthews, MS, Russel Burge, Gregory Cameron

PII: S0190-9622(18)30505-X

DOI: [10.1016/j.jaad.2018.03.047](https://doi.org/10.1016/j.jaad.2018.03.047)

Reference: YMJD 12440

To appear in: *Journal of the American Academy of Dermatology*

Received Date: 8 June 2017

Revised Date: 23 March 2018

Accepted Date: 27 March 2018

Please cite this article as: Zachariae C, Gordon K, Kimball A, Lebwohl M, Blauvelt A, Leonardi C, Braun D, McKean-Matthews M, Burge R, Cameron G, Efficacy and Safety of Ixekizumab Over 4 Years of Open-Label Treatment in a Phase 2 Study in Chronic Plaque Psoriasis, *Journal of the American Academy of Dermatology* (2018), doi: 10.1016/j.jaad.2018.03.047.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1 **Efficacy and Safety of Ixekizumab Over 4 Years of Open-Label Treatment in a Phase 2**
2 **Study in Chronic Plaque Psoriasis**

3
4 Claus Zachariae, MD¹; Kenneth Gordon, MD²; Alexandra Kimball, MD³; Mark Lebwohl, MD⁴;
5 Andrew Blauvelt, MD⁵; Craig Leonardi, MD⁶; Daniel Braun, MD⁷; Missy McKean-Matthews, MS⁸;
6 Russel Burge⁷; Gregory Cameron⁷

7
8 ¹University Hospital of Copenhagen Gentofte, Hellerup, Denmark

9 ²Medical College of Wisconsin, Milwaukee, Wisconsin, United States of America

10 ³Harvard Medical School, Boston, Massachusetts, United States of America

11 ⁴Mount Sinai Medical Center, New York, New York, United States of America

12 ⁵Oregon Medical Research, Portland, Oregon, United States of America

13 ⁶Department of Dermatology, Saint Louis University School of Medicine, Saint Louis, Missouri,
14 United States of America

15 ⁷Eli Lilly and Company, Indianapolis, Indiana, United States of America

16 ⁸inVentiv Health Clinical, Ann Arbor, Michigan, United States of America

17
18 **Send Reprint Requests and Correspondence to:**

19 Claus Zachariae, MD, DMSci

20 Department of Dermatology and Allergy

21 Gentofte Hospital, University of Copenhagen

22 Kildegaardsvej 28

23 Hellerup, Denmark 2900

24 Tel: +45-38673203

25 Email: claus.zachariae@regionh.dk

26
27 **Word counts:** Abstract=197; Capsule Summary=50; Text= 2315

28 **Number of references:** 19

29 **Number of figures/tables:** 3/2

30
31 **Funding source:** Funding for this study was provided by Eli Lilly and Company

32
33 **IRB approval:** This manuscript describes outcomes from the I1F-MC-RHAJ (NCT01107457)
34 clinical trial conducted under local institutional review board approval in accordance with the
35 Declaration of Helsinki and applicable laws and regulations.

36
37 **Clinicaltrials.gov number:** NCT01107457

38 **Prior presentation statement:** The data within this manuscript have not been previously
39 presented.

40
41 **List of Attachments:**

42 Protocol

43 Statistical analysis plan

44 Journal manuscript submission form and checklist

45 CONSORT checklist

46 IRB approval letter

47 Conflict of interest statements

48 Copyright transfer statement

Download English Version:

<https://daneshyari.com/en/article/8714896>

Download Persian Version:

<https://daneshyari.com/article/8714896>

[Daneshyari.com](https://daneshyari.com)